$EL

Estée Lauder (EL)’s China Bet Just Paid Off. Its Makeup Business Still Hasn’t Caught Up

Estée Lauder (EL) reported Q4 net sales of $3.63B, up 6.3%, driven by luxury fragrance and skincare. It forecasted fiscal 2027 adjusted EPS of $3.10-$3.35, above estimates, sending shares up 11% premarket. However, makeup sales were flat, and hair care dropped 1%. The company also reported a $38M tariff-refund benefit and a net loss of $116M, down from $546M a year earlier.

Original reporting
Published Aug 28, 2026, 3:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 3:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Estée Lauder (EL)’s China Bet Just Paid Off. Its Makeup Business Still Hasn’t Caught Up — source image
Decision brief

The 30-second read

$ELBullishHigh
01

Why it matters

The guidance raise and earnings beat provide a fresh catalyst, likely prompting short‑term buying pressure while longer‑term concerns remain over underperforming categories.

02

Market read

The earnings release is a primary market‑moving event for EL, with immediate price impact and implications for the broader beauty sector.

03

What to watch

The $38 million tariff‑refund boost is a one‑time benefit; future earnings may revert without similar offsets.

Relevance 8/10Novelty 8/10Timing: premarket August 19, 2026

Background

Estée Lauder disclosed its Q4 results, highlighting growth in fragrance and skincare, a flat makeup segment, and a modest profit loss narrowing year‑over‑year.

Company-level read

Ticker impact

$ELBullishHigh confidence
Context

Estée Lauder reported Q4 sales up 6.3% and raised FY2027 EPS guidance to $3.10‑$3.35, beating estimates and sending the stock 11% higher pre‑market.

Expected impact

Potential continuation of the pre‑market rally into the regular session, with upside target near recent highs.

Evidence & confidence

The fresh earnings numbers and guidance are primary disclosures with material scale, driving a notable price move.

Market effects

Luxury cosmetics sector may see renewed investor interest as Estée Lauder's fragrance/skincare rebound highlights growth opportunities.

Strong China sales signal continued demand in the APAC beauty market, supporting peers with exposure to the region.

The earnings beat adds to the broader narrative of consumer discretionary resilience amid a mixed macro backdrop.

Counterpoint

Despite the earnings beat, persistent weakness in makeup and hair care could pressure margins and limit upside.

Key entities

  • Stéphane de La Faverie

    CEO of Estée Lauder, commented on category performance and strategic focus.

Related articles

$ELMed

Why is Estee Lauder stock climbing today?

Estee Lauder (EL) stock rose 2.6% in pre-market trading after Barclays upgraded it to Overweight and raised its price target to $108, citing broad recovery and strong Q4 2026 results. The company reported adjusted EPS of $0.39 and revenue of $3.63B, both beating estimates. Barclays highlighted balanced revenue growth and margin expansion potential. Bernstein SocGen maintained a Market Perform rating with a $106 target. The broader market traded modestly lower.

$ELMed

Estee Lauder outlook revised to stable by S&P on deleveraging

S&P Global Ratings revised Estee Lauder's outlook to stable from negative, citing improved operating results and credit metrics. The agency expects adjusted leverage to fall to 1.9x by fiscal 2027, with mid-single-digit revenue growth and expanded EBITDA margins. Cash flows are projected to decline due to restructuring and investments, but the company plans to use cash balances for debt repayment.

$ELMedAI 8/10

Estee Lauder vs Nike: One Turnaround Just Proved Itself, the Other Keeps Slipping

Estee Lauder (EL) reported four consecutive earnings beats, raising its fiscal 2027 EPS guidance to $3.10-$3.35. Nike (NKE) guided revenue down, with Greater China down 12% and Converse down 32%. EL's stock rose 10.46% post-earnings, while NKE's turnaround timeline extends. EL's forward P/E is near 32, with a 1.3% yield. NKE offers a 4.3% yield but faces declining revenue.

$MRNAHighAI 8/10

3 Stocks Soared, 3 Stocks Slumped

Moderna (MRNA) surged 176.97% to $174.38 after reporting positive trial results for a cancer therapy with Merck (MRK). Estee Lauder (EL) rose 16% to $98.01 with revenue up 6.5% Y/Y. MicroStrategy (MSTR) gained 12.68% as Bitcoin prices rose. Nebius (NBIS) fell 10% after a $4.5B convertible note offering. Seagate (STX) dropped 8% to $832.56.